Compare Kroger Co (KR) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs ResMed Inc. — how do they compare? Kroger Co trades at $55.8 (market cap $34.46B), while ResMed Inc. trades at $222.22 (market cap $32.61B). The key difference: Kroger Co and ResMed Inc. are close in size by market cap, and Kroger Co pays the higher dividend (2.56%). Which is the better fit depends on your goals.
| KR | RMD | |
|---|---|---|
Market Cap | $34.46B | $32.61B |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $293.73 |
52-Week Low | $55.53 | $182.82 |
Enterprise Value | $54.56B | $31.97B |
Dividend Yield | 2.56% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $56.48, down 0.44% on the day, with a bearish technical signal driven by moving averages. The company reported mixed Q1 2026 earnings, missing EPS estimates by $0.01, but maintains a strong cash flow position with $2.08B net cash flow in 2025. Recent corporate actions include dividend payments, and news highlights e-commerce leadership changes and product recalls.
The outlook is balanced; analyst consensus is a Buy with a $68.25 price target, implying 21% upside, supported by stable revenue and margin expansion. Risks include competitive pressures, debt increase, and operational challenges from recent recalls. The stock offers value with a low P/S ratio but faces near-term technical headwinds.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
